The impact of sugar diet on humidity preference, survival, and host landing in mosquitoes.

Mosquito-borne diseases have caused more than one million deaths each year. There is an urgent need to develop an effective way to reduce mosquito-host interaction to mitigate disease transmission. Sugar diets have long been linked to abnormal physiology in animals, making them potential candidates for mosquito control. Here, we show the impact of sugar diets on humidity preference and survival in Aedes aegypti and Culex pipiens . With two-choice assays between 100% and 75% relative humidity (RH), we demonstrate that the effect of sugar diets on humidity preference is species-specific where Ae. aegypti showed significant differences and the reduced effects were noted in Cx. pipiens . Among the sugar diets, arabinose significantly reduced the survival rate of mosquitoes even at low concentrations. Moreover, we found that host landing was not impacted by feeding on different sugar types. Our study suggests that specific sugar treatments could be applied to mosquito control by dampening their humidity preference and reducing their lifespan, thus reducing mosquito-borne disease transmission.

Humidity as a zeitgeber for circadian entrainment of insect systems.

Humidity levels, like light and temperature, fluctuate daily yet are less predictable; however, whether humidity entrains circadian clocks and enables animals to synchronize behaviors to environmental variations remains unknown. Here, we investigate the circadian humidity entrainment in various insects. Multiple species robustly respond to humidity cycles, and when the humidity cue is removed, their rhythmic behaviors continue, suggesting that humidity-associated rhythmic activities are under circadian control. Moreover, the Drosophila clock and hygrosensation mutants lack rhythmic activities during and after humidity entrainment, indicating that the core clock components and hygrosensors are essential to circadian entrainment. Our findings identify that humidity serves as a novel zeitgeber for circadian entrainment for insects that could have broad applicability and importance among animal systems. One Sentence Summary: Humidity entrainment of the circadian clock enables the synchronization of insect behaviors to environments.

Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment.

Despite significant advancements in the treatment of other cancers, pancreatic ductal adenocarcinoma (PDAC) remains one of the world's deadliest cancers. More than 90% of PDAC patients harbor a Kirsten rat sarcoma (KRAS) gene mutation. Although the clinical potential of anti-KRAS therapies has long been realized, all initial efforts to target KRAS were unsuccessful. However, with the recent development of a new generation of KRAS-targeting drugs, multiple KRAS-targeted treatment options for patients with PDAC have entered clinical trials. In this review, we provide an overview of current standard of care treatment, describe RAS signaling and the relevance of KRAS mutations, and discuss RAS isoform- and mutation-specific differences. We also evaluate the clinical efficacy and safety of mutation-selective and multi-selective inhibitors, in the context of PDAC. We then provide a comparison of clinically relevant KRAS inhibitors to second-line PDAC treatment options. Finally, we discuss putative resistance mechanisms that may limit the clinical effectiveness of KRAS-targeted therapies and provide a brief overview of promising therapeutic approaches in development that are focused on mitigating these resistance mechanisms.

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.

RAS oncogenes (collectively NRAS, HRAS and especially KRAS) are among the most frequently mutated genes in cancer, with common driver mutations occurring at codons 12, 13 and 611. Small molecule inhibitors of the KRAS(G12C) oncoprotein have demonstrated clinical efficacy in patients with multiple cancer types and have led to regulatory approvals for the treatment of non-small cell lung cancer2,3. Nevertheless, KRASG12C mutations account for only around 15% of KRAS-mutated cancers4,5, and there are no approved KRAS inhibitors for the majority of patients with tumours containing other common KRAS mutations. Here we describe RMC-7977, a reversible, tri-complex RAS inhibitor with broad-spectrum activity for the active state of both mutant and wild-type KRAS, NRAS and HRAS variants (a RAS(ON) multi-selective inhibitor). Preclinically, RMC-7977 demonstrated potent activity against RAS-addicted tumours carrying various RAS genotypes, particularly against cancer models with KRAS codon 12 mutations (KRASG12X). Treatment with RMC-7977 led to tumour regression and was well tolerated in diverse RAS-addicted preclinical cancer models. Additionally, RMC-7977 inhibited the growth of KRASG12C cancer models that are resistant to KRAS(G12C) inhibitors owing to restoration of RAS pathway signalling. Thus, RAS(ON) multi-selective inhibitors can target multiple oncogenic and wild-type RAS isoforms and have the potential to treat a wide range of RAS-addicted cancers with high unmet clinical need. A related RAS(ON) multi-selective inhibitor, RMC-6236, is currently under clinical evaluation in patients with KRAS-mutant solid tumours (ClinicalTrials.gov identifier: NCT05379985).